BBIO vs PFE
BBIO: BridgeBio is a portfolio-based biotech firm focused on translating genetic science into precision therapies for patients with severe genetic disorders. PFE: A diversified, global biopharmaceutical giant focused on discovering and commercializing life-changing medicines, vaccines, and advanced therapies across key therapeutic areas.
Side-by-side fundamentals
| Metric | BBIO | PFE | Edge |
|---|---|---|---|
| Price as of 2026-08-10 close | $84.67 | $27.05 | |
| Market cap as of 2026-08-11 | $16.6B | $154.2B | |
| P/E as of 2026-08-11 | n/a | 35.47 | |
| PEG as of 2026-08-11 | -3.70 | -2.72 | BBIO lower |
| Net margin as of 2026-08-11 | -124.4% | +6.8% | PFE higher |
| Gross margin as of 2026-08-11 | +95.1% | +74.7% | BBIO higher |
| Operating margin as of 2026-08-11 | -90.5% | +6.8% | PFE higher |
| ROE as of 2026-08-11 | -206.7% | +4.9% | PFE higher |
| ROA as of 2026-08-11 | -65.8% | +2.1% | PFE higher |
| Debt / equity as of 2026-08-11 | 8.27 | 0.74 | PFE lower |
| Revenue growth (YoY) as of 2026-08-11 | +355.2% | -0.2% | BBIO higher |
| Revenue CAGR (3y) SEC XBRL | +86.3% | -14.8% | BBIO higher |
| Dividend yield as of 2026-08-11 | n/a | +6.4% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-08-11 | 0.95 | 0.28 | |
| 1-year return as of 2026-08-10 close | +81.8% | +10.0% | BBIO higher |
Fundamentals: market data, as of 2026-08-11. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-10.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.